泡泡瑪特(09992.HK)出資5000萬元參與投資基金
格隆匯6月2日丨泡泡瑪特(09992.HK)宣佈,於2021年6月2日,北京泡泡瑪特(公司的間接全資附屬公司)作為其中一位有限合夥人與其他有限合夥人,並與舟山蜂巧禮信(作為普通合夥人)簽訂合夥協議,參與投資基金,據此,北京泡泡瑪特認繳出資金額為人民幣5,000萬元,約佔基金總認繳出資額的10.3125%。
上海蜂巧晴虹資產管理合夥企業(有限合夥)為一間於中國註冊成立的有限合夥企業,其經營範圍為資產管理,投資諮詢、管理(除依法須經批准的項目外,憑營業執照依法自主開展經營活動),該企業已依照適用法律辦理作為私募投資基金應履行的備案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.